|
Gene: CABLES1 |
Gene summary for CABLES1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | CABLES1 | Gene ID | 91768 |
Gene name | Cdk5 and Abl enzyme substrate 1 | |
Gene Alias | CABL1 | |
Cytomap | 18q11.2 | |
Gene Type | protein-coding | GO ID | GO:0007049 | UniProtAcc | A7K6Y5 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
91768 | CABLES1 | HCC2_Meng | Human | Liver | HCC | 1.70e-04 | 4.24e-02 | 0.0107 |
91768 | CABLES1 | HCC2 | Human | Liver | HCC | 2.97e-22 | 4.90e+00 | 0.5341 |
91768 | CABLES1 | S014 | Human | Liver | HCC | 6.32e-19 | 7.98e-01 | 0.2254 |
91768 | CABLES1 | S015 | Human | Liver | HCC | 1.74e-19 | 9.45e-01 | 0.2375 |
91768 | CABLES1 | S016 | Human | Liver | HCC | 1.88e-18 | 6.49e-01 | 0.2243 |
91768 | CABLES1 | S028 | Human | Liver | HCC | 1.80e-03 | 1.85e-01 | 0.2503 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Oral cavity | OSCC | |
Oral cavity | LP | |
Oral cavity | EOLP | |
Oral cavity | NEOLP | |
Esophagus | HGIN |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CABLES1 | SNV | Missense_Mutation | novel | c.1663N>T | p.Asn555Tyr | p.N555Y | Q8TDN4 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-A2-A0EO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
CABLES1 | SNV | Missense_Mutation | c.923N>A | p.Arg308Gln | p.R308Q | Q8TDN4 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.992) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CABLES1 | SNV | Missense_Mutation | novel | c.1893G>C | p.Gln631His | p.Q631H | Q8TDN4 | protein_coding | deleterious(0.03) | probably_damaging(0.993) | TCGA-AR-A2LE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | PD |
CABLES1 | SNV | Missense_Mutation | novel | c.1283T>C | p.Leu428Pro | p.L428P | Q8TDN4 | protein_coding | tolerated(0.15) | benign(0.216) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CABLES1 | SNV | Missense_Mutation | c.1433T>C | p.Phe478Ser | p.F478S | Q8TDN4 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CABLES1 | SNV | Missense_Mutation | novel | c.1494N>A | p.Met498Ile | p.M498I | Q8TDN4 | protein_coding | tolerated(0.1) | probably_damaging(0.977) | TCGA-E2-A9RU-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | SD |
CABLES1 | insertion | Frame_Shift_Ins | novel | c.1664_1665insGGCCAGGCACTGTACAGGGCACTTCT | p.Asn555LysfsTer24 | p.N555Kfs*24 | Q8TDN4 | protein_coding | TCGA-A2-A0EO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
CABLES1 | insertion | Frame_Shift_Ins | novel | c.1309_1310insCTCAGTCTTACACTGTGACCACAGAGCCCCA | p.Arg437ProfsTer23 | p.R437Pfs*23 | Q8TDN4 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
CABLES1 | SNV | Missense_Mutation | novel | c.1628N>C | p.Val543Ala | p.V543A | Q8TDN4 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CABLES1 | SNV | Missense_Mutation | rs529420681 | c.847N>T | p.Arg283Trp | p.R283W | Q8TDN4 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.998) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |